Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Melatonin is a naturally occurring indoleamine hormone primarily produced by the pineal gland in the brain. It regulates circadian rhythms and sleep-wake cycles by acting as a full agonist at melatonin receptor 1 (MT1) and melatonin receptor 2 (MT2), both of which are G-protein coupled receptors. Melatonin also functions as an antioxidant within mitochondria, directly scavenging free radicals and upregulating antioxidant enzymes such as superoxide dismutase and catalase. As a supplement or drug—usually synthesized in laboratories—it is used to manage sleep disorders like insomnia and delayed sleep-wake phase disorder (DSWPD), jet lag, preoperative anxiety, and certain circadian rhythm disturbances. In some countries it is regulated as a dietary supplement; in others it may be classified as a medication[1][3][4][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on melatonin.